VF
RKDA icon

VitalStone Financial’s Arcadia Biosciences RKDA Stock Holding History

VitalStone Financial’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1
Closed – – 566
2024
Q1 		$0 Hold
1
– – ﹤0.01% 586
2023
Q4 		$0 Hold
1
– – ﹤0.01% 573
2023
Q3 		$0 Hold
1
– – ﹤0.01% 595
2023
Q2 		$0 Buy
+1
New +$5 ﹤0.01% 1026
2023
Q1 		– Hold
0
– – – 484
2022
Q4 		– Hold
0
– – – 578

Other funds holding RKDA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
OLVIG
Oliver Lagore Vanvalin Investment Group Flint, Michigan $255M AUM
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

VitalStone Financial's RKDA Position: Q2 2024 in Review

VitalStone Financial sold out of Arcadia Biosciences (RKDA) in Q2 2024, closing a stake of 1 share.

VitalStone Financial first reported a position in RKDA in Q2 2023 and held it in 4 quarters. The position peaked at $0 in Q1 2024. 11 funds tracked by Wall St. Rank hold RKDA as of Q2 2024.

  • VitalStone Financial reported no remaining Arcadia Biosciences position as of Q2 2024 after selling out during the quarter.
  • VitalStone Financial sold 1 Arcadia Biosciences share in Q2 2024.
  • VitalStone Financial first reported a position in Arcadia Biosciences in Q2 2023 and held it in 4 quarters.
  • VitalStone Financial's Arcadia Biosciences position peaked at $0 in Q1 2024.
  • 11 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q2 2024.

Based on VitalStone Financial's 13F filing for Q2 2024, filed 7 Aug 2024.